Landos Biopharma(LABP) - 2020 Q4 - Annual Report

For the transition period from ___________ to ___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39971 WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-5085535 | ...